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Summary Interstrand cross-linking, repair and lethal effects of (-)-(R)-2-aminomethylpyrrolidine(l,l-cyclo-
butanedicarboxylato) platinum(II) (DWA2114R) were studied in normal human. Fanconi's anaemia (FA) and
xeroderma pigmentosum group A (XPA) cells. Interstrand crosslinking by DWA2114R was slower than that
by cisplatin (CDDP), since DWA2114R produced mainly Pt(II)-monoadducts after 1 h treatment, followed by
progressive interstrand crosslinking to a maximum 5 h post-incubation, while CDDP induced rapidly inter-
strand crosslinks in -70% DNA during the 1 h treatment, followed by a -30% residual increase. At the
maximum rate, DWA2114R was 18 times less interstrand-crosslinking than CDDP on the 1 mm basis. FA
cells were specifically defective in the first half-excision of DWA2114R and CDDP-induced Pt(II) interstrand
crosslinks, but XPA cells were as proficient as normal cells (t = 5-7 h). On the contrary, XPA cells were
deficient in excision repair ofintrastrand crosslinks, but FA cells were normal. In clonogenic survival curves of
all types of cells, mean lethal doses (Do) of DWA2114R were an order of magnitude greater than those of
CDDP. FA cells were most (3.5 times) sensitive (Do = 25.1 ± 0.96 JiM) and XPA cells were 1.9 times more
sensitive (Do = 47.1 ± 0.17 JiM) to DWA2114R than normal cells (Do = 87.6 + 5.65 1M). DWA2114R and
carboplatin with a cyclobutanedicarboxylato group exhibited almost similar lethal effects on each of normal,
FA and XPA strains. FA (Do = 3.44 ± 0.44 JiM) and XPA cells (Do = 3.84 ± 0.17 JM) were similarly 3-fold
more sensitive to CDDP than normal (Do = 9.97 ± 0.15 JiM). On the basis of a single lethal hit (Do), thus
DWA2114R and carboplatin effectively killed more FA cells defective in interstrand crosslink repair than XPA
cells defective in intrastrand crosslink repair.
Cis-diaminedichloroplatinum(II) (CDDP) (Rosenberg et al.,
1969) is a widely used anticancer agent which has two rapidly
leaving chloro-ligands in cis, and carboplatin of a second
generation derivative has a bidentate cyclobutanedicarboxy-
lato (CBDCA) moiety replaced for dichloro-ligands (Figure
1) (Harap et al., 1980; Foster et al., 1990). Cis-Pt(II) of
CDDP after rapid independent hydrolysis of chloro-ligands
binds to mainly the N7 position of dG to form the first
monoadduct and then bifunctional cross-linkage in a half-life
(t1) of approximately a few hours (Eastman, 1985, 1987;
Fichtinger-Schepman et al., 1985; Knox et al., 1986; Roberts
& Friedlos, 1987; Lepre & Lippard, 1990). Total DNA
platinations by CDDP consist of 90% or more intrastrand
crosslinks in the sequences of 5'-d(GpG)-3' (>65%), 5'-
d(ApG)-3' (20-25%) and 5'-d(ApNpG)-3'(-4%; N for any
base) after in vitro reaction (Eastman et al., 1985; 1987;
Lepre & Lippard, 1990), and < 2% interstrand cross-links in
DNA in vivo (Fichtinger-Schepman et al., 1985; Knox et al.,
1986; Roberts & Friedlos, 1987). Interstrand crosslinking
occurs between two dG residues of the complementary 5'-
d(GpC)-3' sequences (Lemaire et al., 1991). A rate of in vitro
DNA platination by carboplatin possessing a hydrolysis-
resistant CBDCA group is 100 times slower than that by
CDDP (Knox et al., 1986).
Recently synthesised DWA2114R is an enantiomeric iso-
mer of (-)-(R)-2-aminomethylpyrrolidine(l,l-CBDCA)Pt(II)
(Figure 1), which has the specific carrier ligand replaced for
symmetric diamines in carboplatin (Morikawa et al., 1990).
DWA2114R has been shown to be as potent as carboplatin in
anticancer activity toward cultured tumour cells and solid
tumours (Endoh et al., 1989; Morikawa et al., 1990; Mat-
sumoto et al., 1991). Regarding side effects, CDDP causes
severe neurotoxicity, myelotoxicity, and especially nephrotox-
icity, which limit the therapeutic efficacy (von Hoff et al.,
1979; Gildstein & Mayor, 1985). However, carboplatin cur-
rently in clinical use is devoid of nephrotoxicity, although it
still causes myelosuppression (von Hoff et al., 1979; Harap et
al., 1980). DWA2114R with the specific carrier ligand has
been shown to be less nephrotoxic and myelotoxic to admin-
istered animals than carboplatin (Endoh et al., 1989; Aka-
matsu et al., 1991; Matsumoto et al., 1991). Thus, DWA2114R
appears to be a promising new analog.
Both Pt(II) intra- and interstrand crosslinks formed at the
specific DNA sequences block DNA synthesis in vitro (Hei-
ger-Bernays et al., 1990; Lemaire et al., 1991; Iwata et al.,
1991) and in vivo (Roberts & Friedlos, 1987), and inhibit
RNA transcription in vitro (Corda et al., 1991) at damaged
sites. Some studies have indicated that the main cytotoxic
lesions are abundant Pt(II) intrastrand crosslinks (Heiger-
Bernays et al., 1990; Lepre & Lippard, 1990), while the
others have indicated that the minor Pt(II) interstrand cross-
links are more lethal (Knox et al., 1986; Roberts & Friedlos,
1987). Further, G2 block through the CDDP-induced inhibi-
tion of transcription also exerts cytotoxicity (Sorenson &
Eastman, 1988). Therefore, it remains to be determined
which of intra- and interstrand crosslinks are more cytotoxic.
Regarding excision repair, some fraction ofCDDP-induced
intrastrand cross-links is removed by nucleotide excision
repair, but a substantial fraction is not in mammalian cells
(Ciccarelli et al., 1985; Heiger-Bernays et al., 1990; Jones et
al., 1991). Especially, the major d(GpG) intrastrand cross-
link is poorly repaired (Bedford et al., 1988; Page et al.,
1990) and not in vitro by extracts of normal human cells
(Szymkowski et al., 1992). The extract of xeroderma pigmen-
tosum complementation group A (XPA) cells has a 5-10
fold reduced capacity to provoke repair synthesis in vitro in
overall platinated plasmid DNA (Szymkowski et al., 1992).
However, XPA cells were only twice as sensitive to CDDP
killing, despite defective excision of CDDP-induced intra-
strand crosslinks (Plooy et al., 1985), as normal cells (Plooy
et al., 1985; Fujiwara et al., 1987). In this regard, we have
shown that Fanconi's anaemia (FA) cells are extraordinarily
sensitive to the lethal effect of interstrand-crosslinking mito-
mycin C (MC) due to a selective defect in the first half-
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Figure 1 Structures of CDDP (cisplatin), carboplatin and DWA2114R.
excision of MC interstrand crosslinks compared to XPA cells
(defective in only excision of MC monoadducts) and normal
cells (Fujiwara et al., 1977; Fujiwara, 1982; 1983). FA cells
are also more sensitive to CDDP than XPA cells (Plooy et
al., 1985; Fujiwara et al., 1987). Such alternative repair
defects of FA and XPA cells will enable us to distinguish the
lethal effects of Pt(II) inter- and intrastrand crosslinks. Fur-
ther, it is interesting to study to what extent the specific
structural modifications with 2-aminomethylpyrrolidine and
CBDCA ligands in DWA2114R affect DNA-adducting, in-
terstrand crosslinking and lethal effect, compared to CDDP
and carboplatin.
This study aimed to delineate (i) differential interstrand
crosslinking between particular DWA2114R and CDDP, (ii)
defective repair of Pt(II) inter- or intrastrand crosslinks in
FA or XPA cells, respectively, and (iii) differential lethal
effects of DWA2114R, carboplatin and CDDP on normal
human, FA and XPA cells. The results show that DWA-
2114R with the specific structural modifications is less cross-
linking and lethal than CDDP on the equimolar basis, but it
exerts a differentially higher lethal effect on the FA cells than
on the XPA cells. Further we show, by utilising such
specifically repair-defective mutants, that Pt(II) interstrand
crosslinks are more lethal than intrastrand crosslinks as a
basic anticancer action of DWA2114R and CDDP.
Materials and methods
Drugs
A new derivative DWA2114R (Endoh et al., 1989) (a gift of
Chugai Pharmaceutical Co., Tokyo, Japan) was studied, in
comparison with the first generation CDDP (purchased from
Aldrich) and second generation carboplatin (Bristol-Myers
Squibb). Figure 1 illustrates their structures.
Humanfibroblasts
The human diploid fibroblast strains used were: normal,
NFAS (Fujiwara, 1989) and TIG-1 (courtesy of Dr T. Kaji,
Tokyo Metropolitan Institute of Gerontology, Tokyo); FA,
FA14TO and FA18TO (Fujiwara et al., 1977; 1987) (courtesy
of Dr M.S. Sasaki, Kyoto University, Kyoto); XPA, XP6KO
and XP35KO (Fujiwara, 1989). Cells were cultured in Eagle's
minimal essential medium (MEM) supplemented with 15%
foetal bovine serum (FBS) (Fujiwara et al., 1977).
Detection ofDWA2114R and CDDP-induced Pt(II)
interstrand crosslinks
Our previous method of alkaline sucrose sedimentation
(Fujiwara, 1982; 1983) was used to measure yields and repair
of DWA2114R or CDDP-induced Pt(II) interstrand cross-
links because of their alkali stability (Roberts & Friedlos,
1987). The representative NFAS, FA18TO and XP35KO(A)
cells were prelabelled with 111 kBqml-l of [5-methyl-
3H]dThd (specific activity, 1.85 TBq mmole ', Amersham)
for 3 days or with 7.4 kBq ml-l of [2-'4C]dThd (specific
activity, 1.5 GBq mmole 1, New England Nuclear) for 4
days, followed by chase for 2 h prior to drug treatment. Only
3H-DNA cells were treated with either 0 to 2.2 mM
DWA21 14R or 0 to 0.333 mM CDDP in phosphate-buffered
saline (PBS: 0.14 M NaCl, 3.8 mM KCI, 1.6 mM sodium phos-
phate, pH 7.4) at 37°C for 1 h, washed twice with PBS, and
then incubated in the FBS-MEM growth medium for desired
periods up to 24 h. Cells were lysed and digested with
2 mgml-' of preheated pronase for 4 h at 37°C (Fujiwara,
C.)
co
0
Cu Ca
a)
0)
0~
0
(bottom)
Fraction number
(top)
Figure 2 Alkaline sucrose sedimentation profiles of DWA21 14R
or CDDP-induced interstrand crosslinks in FA18TO DNA.
[3H]dThd-labelled FA18TO cells were treated with 2.2 mM
DWA2114R or 0.167 mm CDDP in PBS for h at 37'C, fol-
lowed by the immediate lysis or lysis after further 3 and 5 h
post-incubations. 3H-DNA in lysate was sheared to give Mn(0) ;
5.6 x 107 (see below) to avoid abnormal sedimentation of cross-
linked DNA. DNA was denatured and centrifuged at
35,000 r.p.m. for 1 h at 20°C in a Beckman SW50.1 rotor. a,
Interstrand crosslinking with 2.2 mM DWA2114R; b, interstrand
crosslinking with 0.167mM CDDP. 0- 0, untreated [3H]
DNA: Mn(,) = 5.57 x 107 a, b; * *, immediately after 1 h
treatment: Mn,= 6.13 x 107 for DWA2114R a, and 8.66 x 107
for CDDP b; *, 3 h post-incubation: Mn(,) = 9.47 x 107
for DWA2114R a, and 9.92 x 107 for CDDP b; A A, 5 h
post-incubation: Mn(,) = 1.03 x 107 for DWA2114R a, and
1.17 x 107 for CDDP b. Arrow indicates the peak position of the
internal control of untreated '4C-ssDNA (the same profile as the
untreated 3H-ssDNA; Mn(O) = 5.55 x 107), when co-centrifuged
with only the maximally CDDP-crosslinked 3H-DNA after 5 h
postincubation (in b).
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1982). Double-stranded DNA (dsDNA) in lysate was sheared
optimally (see Figure 2, legend) as described previously
(Fujiwara, 1983), and denatured with 0.1 N NaOH (final) for
5 min at 20°C. A 0.2-ml aliquot (-I0' cells) was layered on
the top of 4.8 ml of 5-20% (W/V) alkaline sucrose gradient,
followed by centrifugation at 35,000 r.p.m. for 1 h at 20°C in
an SW50.1 rotor of a Beckman L5-60 ultracentrifuge (Beck-
man Instruments) (Fujiwara, 1982; 1983). After run, each
gradient was fractionated into 25 fractions, and acid-
insoluble radiactivity of each fraction was counted by a
liquid scintillation spectrometer. As described previously
(Fujiwara et al., 1977), the weight average molecular weight
(Mw) of single-stranded DNA (ssDNA) was first calculated
as Mw = [YfiMi/fi, where Mi and fi represent molecular
weight and per cent radioactivity of ith fraction, respectively.
Then, the number average molecular weight (Mn) was cal-
culated as Mn = 1/2 Mw. The number of Pt(II) interstrand
cross-links per Da ( = N/Da) was calculated as NIDa = [1/
Mn(0)] - [1/Mn(t)], and the cross-link unit per average-sized
molecule (N/ssDNA) was as N/ssDNA = [(Mn(t)/Mn(O))-1],
where Mn = (O) and Mn(t) represent Mn values of untreated
control 3H-DNA (or '4C-DNA) and cross-linked 3H-DNA,
respectively (Fujiwara, 1983).
Unscheduled DNA synthesis (UDS)
Cells were grown exponentially on plastic coverslips for 2
days. UDS was measured by incubating cells for 3 h with
[3H]dThd immediately or 5 h after drug treatment. (i) For
UDS during the 0 to 3 h interval immediately after treat-
ment, cells were prelabelled for 30 min with 37 kBq ml-I of
[3H]dThd (specific activity, 1.85 TBq mmole 1) and treated
with DWA21 14R or CDDP (see Table I for doses used) and
2 mM HU for 1 h at 37°C, followed by labelling with 185 or
370 kBq ml-' of [3H]dThd for 3 h in the presence of 2 mM
HU. (ii) For UDS during the 5 to 8 h interval of post-
incubation, prelabelled cells were treated with DWA2114R or
CDDP (see Table I for doses used) for 1 h, incubated with
2 mM HU for 5 h, and labelled with 185 kBq mll of
[3H]dThd for 3 h in the presence of 2 mM HU. The cells were
processed for autoradiography. Such prelabel and HU treat-
ment eliminated miscounting of grains over cells with for-
tuitous residual incorporation at the very beginning and end
of S phase (Fujiwara et al., 1977). Mean number of grains
per cell from total counts of 30 to 50 lightly-labelled non-S
cells was determined for a measure of UDS.
Lethal effects ofDWA2114R, carboplatin or CDDP
Exponentially growing normal, FA and XPA cells (see
Figure 5 and Table II) were plated at appropriate densities in
duplicated 60-mm plastic dishes and incubated for 4 h for
attachment. For clonogenic survival, attached single cells
were treated with either 0 to 300 JLM DWA2114R, 0 to
250 gM carboplatin, or 0 to 35 tLM CDDP in PBS for 1 h or
6 h at 37°C, washed, and incubated in FBS-MEM medium
for 14 days until visible colonies of 50 cells or more
developed. For the time-dependent lethal effect, a fixed low
concentration of either 44JM DWA2114R (20 Lgml-') or
3.33 JLM CDDP (1.01sgml-') was selected to treat single cells
continuously for the indicated lengths of time up to 24 h in
FBS-free MEM. After wash, cells were incubated for 14 days
for colony assay. As all survival curves were characterised by
extrapolation number ; 1, the lethal effect was compared by
only mean lethal dose (Do) of DWA2114R, carboplatin or
CDDP, which reduces survival in the exponential region of
survival curve to l/e (= 37%). Since survival curves consisted
of the two, first and second, exponential components, we
assessed Do values of both components.
Results
Interstrandcrosslinking with DWA2114R or CDDP
[3H]dThd-prelabelled FA18TO cells were treated with 2.2 mM
DWA2114R or 0.167mM CDDP for 1 h and further in-
cubated for 3 and Sh. Figure 2 shows alkaline sucrose
sendimentation profiles for time-dependent interstrand cross-
linking. The untreated 3H-ssDNA and '4C-ssDNA sedi-
mented to form a peak of profile at fraction 15, giving an
Mn(0) of 5.57 x 107 (Figure 2a and 2b). The 3H-DNA with
the maximum number of CDDP-induced interstrand cross-
links sedimented around a peak at fraction 10, providing an
Mn(,) of 1.17 x 108 (Figure 2b). The Mn ,) was twice the
Mn(0) (= 5.57 x 107) of internal control '4C-ssDNA. Thus,
optimal shearing of dsDNA in the mixed cell lysate (see Methods) for centrifugation at 35,000 r.p.m. for 1 h avoided
abnormal sedimentation of interstrand-crosslinked DNA and
the condition allowed us to estimate the accurate number of
interstrand crosslinks. Immediately after the 1 h treatment
with 2.2 mM DWA2114R, the 3H-DNA profile shifted only
slightly, while it moved progressively with post-incubation
time until it approached the peak position at fraction 10 of
maximally interstrand-crosslinked DNA at 5 h (Figure 2a).
The bimodal profile at 5 h after DWA21 14R (Figure 2a)
showed that 90% DNA around the peak at fraction 10 was
interstrand-crosslinked, but only - 10% around a small peak
at fraction 15 remained yet uncrosslinked, providing an Mn(,) of 1.03 x 108 which is close to 2 x Mn(0) (= 1.14 x 108).
Thus, the initial production ofPt(II) interstrand crosslinks by
DWA21 14R was far less, but increased rather rapidly during
a postincubation period of 5 h. On the other hand, Figure 2b
shows that 0.167 mM CDDP rapidly produced interstrand
Table I DWA2114R or CDDP-induced unscheduled DNA synthesis (UDS)
Labelling Cells UDS, mean grains ± SD/cell
Expa interval (numbers counted) DWA2114R CDDP
1 0-3 h NFAS (n = 30) 9.87 ± 1.50b (100)C 8.90 ± 1.40 (100)
FA18TO (n = 30) 10.07 ± 1.76 (102) 9.00 ± 1.49 (101)
XP6KO(A) (n = 30) 2.80 ± 1.13 (28.4) 1.43 ± 0.90 (16.1)
2 0-3 h NFAS (n = 50) 6.50 ± 1.47 (100) 6.92 ± 1.32 (100)
FA14TO (n = 50) 6.06 ± 1.48 (93.2) 7.22 ± 1.30 (104)
FA18TO (n = 50) 5.68 1.56 (87.4) 7.38 ± 1.41 (113)
XP35KO(A) (n = 50) 0.62 ± 0.78 (9.5) 0.66 ± 0.72 (9.5)
3 5-8 h NFAS (n = 50) 4.80 1.64 (100) 4.08 ± 1.45 (100)
FA18TO (n = 50) 4.72 1.44 (98.3) 4.58 ± 1.49 (112)
XP35KO(A) (n = 50) 0.58 0.56 (12.1) 0.52 ± 0.61 (15.0)
aExp. No. 1: 1 h-treatment with 0.22 mm DWA2114R or 0.0167 mm CDDP, followed by
the initial 3 h labelling with [3H]dThd (370 kBq/ml) in 2mm HU and 14-day exposure. Exp.
No. 2: 1 h-treatment with 2.2 mm DWA2114R or 0.167 mm CDDP, followed by the initial
3 h-labelling with [3H]dThd (185 kBq/ml) in 2mm HU and 9-day exposure. Exp. No. 3:
1 h-treatment with 0.44 mm DWA2114R or 0.05 mM CDDP, followed by a S h
post-incubation with 2 mm HU, 3 h-labelling with [3H]dThd (185 kBq/ml) in 2 mm HU and
12-day exposure. bStandard deviation of the mean. cThe numerals in the parentheses
indicate % UDS, relative to NFAS normal.1288 Y. FUJIWARA et al.
Table II Mean lethal doses (Do) of DWA2114R, carboplatin and CDDP
Component of Cell Do ± SD (jsM)a
survival curve strain DWA2114R Carboplatin CDDP
First Normal
component NFAS 87.4 ± 3.98 79.0 ± 4.55 10.0 ± 0.00
TIG-1 88.0 ± 11.30 86.7 ± 5.70 9.93 ± 0.23
Meanb 87.6 ± 5.65 82.3 ± 6.18 9.97 ± 0.15
FA
FA18TO 25.4 ± 0.93 25.5 ± 0.71 3.90 ± 0.14
FA14TO 25.3 ± 2.08 25.0 ± 1.00 3.13 ± 0.15
Mean 25.4 0.96 (0.29)c 25.2 ± 0.83 (0.30) 3.44 ± 0.44 (0.35)
XPA
XP35KO 48.8 ± 1.50 41.7 ± 2.89 3.93 ± 0.11
XP6KO 45.8 ± 2.20 42.0 ± 3.61 3.70 ± 0.14
Mean 47.1 2.55d (0.54) 41.8 ± 2.97d (0.51) 3.84 ± 0.17 (0.39)
Second Normal
component NFAS 101.8 ± 5.37 96.3 ± 8.22 13.6 ± 1.40
TIG-1 102.5 3.57 97.3 ± 7.02 13.4 ± 0.15
Mean 102.0 4.42 96.7 7.11 13.5 ± 0.90
FA
FA18TO 63.0 ± 2.08 75.0 ± 7.07 7.95 ± 0.07
FA14TO 66.3 ± 1.50 72.3 ± 3.30 7.83 ± 0.45
Mean 64.3 ± 2.73e (0.63) 73.4 4.78C (0.75) 7.88 ± 0.33 (0.58)
XPA
XP35KO 80.7 ± 2.08 84.0 ± 5.29 8.87 ± 0.42
XP6KO 80.3 ± 1.53 81.3 ± 8.05 9.50 ± 0.71
Mean 80.5 1.64 (0.79) 81.5 7.04 (0.84) 9.12 0.58 (0.68)
aMean Do ± SD of each cell strain from three to five times repeated survival curves. bMean
Do ± SD of the two strains each of normal, FA and XPA. 'The numbers in parentheses are the
FA/normal and XPA/normal ratios of Do of each agent. dp = 0.005 by Student's t-test. ep = 0.003
by Student's t-test.
crosslinks in -70% DNA immediately after the 1 h treat-
ment, followed by --'30% additional interstand crosslinking
during the subsequent 5 h. With the doses of both agents, the
5 h post-incubation yielded the maximum of 8.5-10 interst-
rand crosslinks per I09 Da in the FA18TO DNA in vivo, or
-1 crosslink unit per an ssDNA molecule in average size of
Mn(,) = 5.57 x 107 [= (- 1.l IX 108/5.57 X 107)_1].
Figure 3 plots the concentration-dependent Pt(II) inter-
strand crosslinking in the FA18TO DNA. Rates of inter-
strand crosslinking immediately after the 1 h treatment were
1.7 crosslinks/109 Da per 1 mM DWA2114R (Figure 3a) and
4.7 crosslinks/109 Da per 0.1 mM CDPP (Figure 3b). Thus,
DWA2114R is -28 times less efficient than CDDP immedi-
ately after the 1 h treatment. Rates of the maximum inter-
strand crosslinking at 5 h of postincubation were 5.7
crosslinks/109 Da per 1 mM DWA2114R (Figure 3a), and 5.4
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crosslinks/109 Da per 0.05 mM CDDP (Figure 3b). Thus,
such a maximum rate with DWA2114R is also slower, and a
concentration of DWA2114R 18 times that of CDDP, will be
required for the production of equal numbers of interstrand
crosslinks in vivo on the 1 mM basis.
Repair ofinterstrand crosslinks
Figure 4 illustrates the time kinetics of early progressive
formation ofinterstrand crosslinks and the subsequent repair
in NFAS (normal), FA18TO and XP35KO(A) cells. As indi-
cated above, the initial levels of interstrand crosslinks
immediately after a 1 h treatment were low (- 1.5/109 Da)
for 2.2 mM DWA2114R (Figure 4a) and high (,- 6/109 Da)
for 0.167 mM CDDP (Figure 4b) in all types of cells. Inter-
strand crosslinking progressed during the subsequent post-
a b
mM
Figure 3 DWA2114R or CDDP concentration- and time-dependent interstrand crosslinking in FA18TO DNA. [3H]dThd-labelled
FA18TO cells were treated with the indicated concentrations of DWA2114R or CDDP in PBS for I h at 37°C, washed and further
incubated in FBS-MEM for 5 h at 37°C to allow maximum crosslinking in cells. DNA was centrifuged as in Figure 2, and the
number ofinterstrand crosslinks was plotted against concentration. Saturation of interstrand crosslinking occurred at - I crosslink
unit per a 5.57 x I07 Da-ssDNA molecule [=(- I x 108)/(5.57 x 107) - 1]. 0 0, immediately after I h treatment; * *,
5 h post-incubation. a, DWA2114R: interstrand crosslinking rates immediately and 5 h after treatment were 1.7 and 5.7 crosslinks/
I09 Da/l mm, respectively; b, CDDP: interstrand crosslinking rates immediately and 5 h after treatment were 4.7/109 Da/0.1 mM and
5.4//109 Da/0.05 mM, respectively.DNA INTERSTRAND CROSSLINKING WITH A NEW PLATINUM COMPOUND 1289
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Figure 4 Time dependent increase and one-arm unhooking of
interstrand crosslinks. [3H]dThd-labelled NFAS, FA18TO and
XP35KO cells were treated with either 2.2 mM DWA2114R or
0.167 mm CDDP in PBS for I h, and incubated in MEM-FBS up
to 24h. The numbers of interstrand crosslinks remaining at the
indicated post-incubation times were assessed by alkaline sucrose
sedimentation (see Figure 2). a, DWA21 14R; b, CDDP. 0,
NFAS normal; *, FA18TO; A, XP35KO(A). The t1 values for
NFAS and XP35KO(A) cells in the 5 to 24 h period were 5 h a
and 7 h b.
incubation for 5 h to give 5 and 1.5-fold different elevations
for DWA2114R and CDDP, respectively, until reaching the
similar maxima of 7-10 crosslinks/109 Da at 5 h in NFAS,
FA18TO and XP35KO(A) cells (Figures 4a and b). After-
wards, both NFAS and XP35KO(A) cells performed the first
half-excision of both DWA2114R and CDDP interstrand
crosslinks at a similar rate of t4 = 5-7 h (Figures 4a and b).
On the contrary, FA18TO cells failed to unhook one arm of
DWA2114R and CDDP interstrand crosslinks between 8 and
24h of the post-incubation period, except for a 20-30%
minor loss between 5 and 10 h by perhaps replicative dilution
(Figures 4a and b). Thus, XPA cells were normal in the first
step of interstrand crosslink repair, while FA cells failed in
unhooking one arm of Pt(II) interstrand links.
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Repair ofintrastrand crosslinks by excision repair
For UDS assay, cells were treated with DWA2114R (0.22,
0.44 and 2.2mM) or CDDP (0.0167, 0.05 and 0.167mM) for
1 h and then radioactivity labelled for 3 h with [3H]dThd
during the 0-3 h and 5-8 h intervals after treatment (see
Table I, legend). The average numbers of Pt(II)-induced
grains per nucleus in both intervals after DWA2114R and
CDDP were small even in normal cells (Table I), as recon-
ciled with poor repair of intrastrand crosslinks (see Introduc-
tion). The XPA (XP6KO, XP35KO) cells showed a lower
level of 9.5-28% UDS of normal during both labelling
intervals (Table I), indicating a defect of the XPA cells in
excision repair of intrastrand crosslinks and monoadducts.
However, FA14TO and FA18TO cells were normal in UDS
(- 100%) in both labelling intervals (Table I). Figure 4 and
Table I indicate clearly that the FA cells have a defect in the
repair of Pt(II) interstrand crosslinks, but the XPA cells have
a defect in excision repair of Pt(II) intrastrand crosslinks.
Differential lethal effects ofDWA2114R, carboplatin and
CDDP
Figures Sa to c show the biphasic clonogenic survival curves
of 1 h-treated representative cells, for comparison of the
lethal effects of DWA2114R, carboplatin and CDDP. Table
II summarizes Do ± SD values of the two strains each of the
normal, FA and XPA genotypes. All of the first components
covered the major range of 80-90% kills (Figure 5). The
following characteristics emerge from the first component Do
values in Figure 5 and Table II. (i) The Do values of
DWA2114R and carboplatin were similar and approximately
an order of magnitude greater than those of CDDP in all
types of cells (Figure 5 and Table II). (ii) The interstrand
crosslink repair-defective FA cells and the intrastrand cross-
link repair-defective XPA cells were hypersensitive to
DWA2114R, carboplatin and CDDP (Figure 5), indicating
that both inter- and intrastrand crosslinks are lethally acting.
(iii) Toward CDDP (Figure 5c and Table II), the FA (mean
Do = 3.44±0.44JM) and XPA cells (mean Do = 3.84 ±
0.17I1M) were similarly three times more sensitive than the
normal (mean Do = 9.97 ± 0.15 JAM). This balance of CDDP
killing suggest, taking into account the alternative repair
defects in the FA and XPA cells, that minor interstrand
crosslinks are more lethal than abundant intrastrand cross-
links, when not repaired. (iv) Toward DWA2114R killing
irboplatin, F.M CDDP, F1M
Figure 5 Clonogenic survival curves after a 1 h treatment with DWA2114R, carboplatin or CDDP. NFAS, FA18TO and
XP35KO cells were treated with the indicated concentrations for 1 h at 37°C, washed, and incubated for 14 days for colony assay.
a, DWA2114R; b, carboplatin; c, CDDP. 0, NFAS normal (mean of 4 exps.; plating efficiencies (PE) = 18-26%); *, FA18TO
(mean of 3 exps.; PE = 10-15%); A, XP35KO(A) (mean of 2 exps.; PE = 19-25%). Bar indicates SD.1290 Y. FUJIWARA et al.
(Figure 5a and Table II), the FA cells (mean Do = 25.4 ±
0.96 gM) were most sensitive (3.5 times), and the XPA cells
(mean Do = 47.1 ± 2.55 tMo) were 1.9 times more sensitive
than the normal cells (mean Do = 87.6 ± 5.65 tLM). (v) Such
situations were more or less similar for carboplatin (Figure
5b). Compared to the DWA2114R killing, however, the FA
cells were slightly less sensitive to carboplatin (P = 0.003),
while the XPA cells were slightly more sensitive to it
(P = 0.005), including the second components (Figure 5 and
Table II). Next, the second components of residual survival
(<20%) for all types of cells were less steep than the first
(Figure 5 and Table II). Since the number of interstrand
crosslinks (presumably total Pt(II)-adducts to DNA) in-
creases as a linear function of concentration (Figure 3), the
less steep second components (Figure 5) suggest that the
excess numbers of inter- and intrastrand crosslinks by
>70tLM DWA2114R and carboplatin or >7 ylM CDDP
may be less lethally acting. Nonetheless, those lethal effects
of the three agents followed a roughly similar tendency as
described above for the first components.
Further, we studied the differential lethal effects of con-
tinuous treatment with a fixed low dose of 44tLM
DWA2114R or 3.33ILM CDDP (approximately Do of XPA
in Table II). Figure 6 shows a biphasically increasing lethal
effects with time, indicating that DWA2114R and CDDP
exerted 90% or more lethal effects within the initial 6 h.
Again, FA18TO cells were most sensitive, and XP35KO(A)
cells were intermediately more sensitive to DWA2114R than
normal cells (Figure 6a). Such a treatment with CDDP
resulted in the balanced killing of FA and XPA cells (Figure
6b). In conclusion, FA cells were more sensitive to
DWA2114R and carboplatin than XPA cells.
Discussion
First, the present results have indicated the differential inter-
strand crosslinking of genomic DNA of human cells by
DWA2114R and CDDP. DWA2114R with CBDCA (Figure
1) was less monoadducting to DNA, judged by a low yield of
the final interstrand crosslinks (Figure 3), as carboplatin with
hydrolysis-resistant CBDCA (Figure 1) showed two orders
magnitude slower rate of in vitro DNA platination that did
CDDP (Knox et al., 1986). The rate of CDDP interstrand
crosslinking was faster as accounted for by a 60-70% yield
immediately after 1 h treatment (Figures 2 to 4), as described
previously (Roberts & Friedlos, 1987). Most of the early
1 h-products with DWA2114R were monoadducts (Figure 3),
while once they were formed, interstrand crosslinking pro-
gressed more rapidly (tk,2 h for pre-crosslinks) in the nor-
mal, FA and XPA cells (Figure 4). Maximum interstrand
crosslinking of DNA in cells with both agtents was observed
at 5 h of the post-incubation period (Figure 4), as found with
CDDP (Eastman, 1985; Knox et al., 1986; Fujiwara et al.,
1987). The maximum rate indicated that a molar concentra-
tion of DWA2114R 18 times that of CDDP was required for
producing the equal numbers of interstrand crosslinks
(Figure 3). Thus, the common hydrolysis-resistant CBDCA
group in both carboplatin and DWA2114R (Figure 1) is
rate-limiting in the DNA adduction. The in vitro binding rate
of the second Pt(II) arm ofcarboplatin has been shown to be
slow with t4 = 13 h (Knox et al., 1986; Roberts & Friedlos,
1987). However, the interstrand crosslinking rate in vivo of
carboplatin (Knox et al., 1986) and DWA2114R (t4 = 2 h in
Figure 4) approaches that of CDDP in vivo. Thus, the
CBDCA leaving group becomes more labile after mono-
adducting to DNA.
We studied the repair of Pt(II) inter- and intrastrand cross-
links. Interstrand crosslink repair is a two-step process invol-
ving the first half excision of one arm of Pt(II) interstrand
crosslinks and the subsequent removal of half-excised mono-
adducts (Fujiwara et al., 1977; Fujiwara, 1983). Unilateral
arms of DWA2114R or CDDP-induced Pt(II) interstrand
crosslinks were unhooked with ti = 5-7 h in normal cells
(Figure 4). This ti is three times slower than that (= 2 h) for
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Figure 6 Differential lethal effects of continuous treatment with
DWA2114R or CDDP. NFAS, FA18TO and XP35KO(A) cells
were treated continuously up to 24 h with 44gM DWA2114R or
3.33tLM CDDP in FBS-free MEM, washed and incubated in
FBS-MEM for 14 days for colony assay. Each time point of
treated cell survival was corrected for reduction in plating
efficiencies (0- 15%) during the 0 to 24 h incubation in FBS-free
medium. a, DWA21 14R; b, CDDP. 0, NFAS normal; 0,
FA18TO; A, XP35KO(A).
MC interstrand crosslinks (Fujiwara, 1982). This difference
could arise from different accessibility of repair enzymes to
Pt(II) and MC interstrand crosslinks. The FA cells
(FA18TO, FA14TO) were also almost completely defective in
the first half excision of Pt(II) interstrand crosslinks, but
XPA cells were proficient in that process (Figure 4) (Fujiware
et al., 1987). Excision repair of Pt(II) instrastrand crosslinks
in mammalian cells is poor (Ciccarelli et al., 1985; Heiger-
Bernays et al., 1990). Particularly, the major d(GpG) intrast-
rand crosslinks are refractory to excision repair by normal
human cell extract (Szymkowski et al., 1992). Thus, a small
amount of repair synthesis may arise by other intrastrand
lesions. Furthermore, the amount of UDS induced by abun-
dant intrastrand crosslinks in proficient normal and FA cells
was limited (Table I), as previously indicated with MC
(Fujiwara et al., 1977) and CDDP (Plooy et al., 1985). XPA
had a 5-10-fold reduced UDS after DWA2114R and CDDP
(Table I), as observed in repair synthesis in platinated M13
DNA using the XPA cell extract (Szymkowski et al., 1992).
The lethal effect was different between DWA2114R or
carboplatin and CDDP. The equi-toxicity in terms of Do
required a concentration of DWA2114R or carboplatin an
order of magnitude greater due to reductions in DNA ad-
ducting (see above) and pharmacodynamic uptake into cells
(Akamatsu et al., 1991; Knox et al., 1986), than that of
CDDP (Figure 5 and Table II). Further, in phase with the
maximum crosslinking at 5 h (Figure 4), more than 90% kills
of FA and XPA cells by DWA2114R and CDDP were
attained within 6 h (Figure 6), indicating the tight association
with early production of 90% or more lethally acting DNA
lesions. The killing efficiencies of Pt(II) inter- and intrastrand
crosslinks are also different. Do of CDDP was similar
between intrastrand crosslink repair-defective XPA and
interstrand crosslink repair-defective FA cells (Table II),
indicating that the abundant former and the minor latter
lesions remaining unrepaired exert the balanced killing, which
is reflective of a higher killing efficiency of interstrand cross-
link. In addition, preferential repair in actively transcribed
genes is not so distinct for both Pt(II) inter- and intrastrand
crosslinks (Jones et al., 1991). The completely excision-
defective XPA cells were not so sensitive (at most 2-fold) to
DWA2114R, carboplatin and CDDP (Figure 5) as to UV
(Fujiwara et al., 1977). Similarly, the XPA cells exhibited
only a 1.5 to 2 times slight hypersensitivity to MC and
monofunctional decarbamoyl mitomycin C, despite the 30-DNA INTERSTRAND CROSSLINKING WITH A NEW PLATINUM COMPOUND 1291
fold MS supersensitivity of the FA cells by effective blocks to
replication by interstrand crosslinks (Fujiwara et al., 1977;
Kano & Fujiwara, 1981). Amounts of MC and Pt(II) interst-
rand crosslinks in the cell DNA are 2-10%, compared to
90% or more intrastrand crosslinks. Therefore, the XPA cells
can tolerate a great amount of monoadducts and intrastrand
crosslinks by the replication-dependent or postreplication
repair pathway, even though the major d(GpG) intrastrand
crosslinks effectively block replication in vitro (Ciccarelli et
al., 1985; Heiger-Bernays et al., 1990; Lemaire et al., 1991;
Iwata et al., 1991). In consequence, interstrand crosslinks are
more potentially lethal than intrastrand adducts.
In the first component of survival curves, low doses of
DWA2114R killed more FA cells than XPA cells (Figures 5
and 6). This particular aspect can be discussed further, taking
into account that the hypersensitive lethal fractions in FA
and XPA cells arise by unrepaired inter- and intrastrand
crosslinks, respectively. First, the relative lethal effects in
terms of the FA/normal ratios of the first component Do are
identically 0.3 for DWA2114R, carboplatin and CDDP
(Table II). Thus, the different Do concentrations of the three
agents will produce a single hit, or the identical lethal
number of interstrand crosslinks in the DNA of FA cells.
However, the XPA/normal ratios are different: 0.54 for
DWA21 14R, 0.51 for carboplatin and 0.39 for CDDP (Table
II). These figures suggest that the number of intrastrand
crosslinks per lethal hit in the XPA cells is less for
DWA21 14R and carboplatin than CDDP. Alternatively, it is
suggested that, on the basis of a single lethal hit (Do), a
relative ratio of highly lethally acting interstrand crosslinks
over intrastrand crosslinks is greater with DWA2114R and
carboplatin than CDDP.
Finally, the structural modification with CBDCA in
DWA2114R and carboplatin may play a similar role in the
reduction of mainly the pharmacodynamic uptake and DNA
binding, but the 2-aminomethylpyrrolidine moiety in
DWA2114R may not greatly affect DNA-adducting. Instead,
the 2-aminomethylpyrrolidine moiety in DWA2114R would
be related to a greater improvement of nephrotoxicity and
myelosuppression, compared to carboplatin without that
particular carrier ligand.
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